Harmony Sciences shares plunged Wednesday after the FDA rejected its bread-and-butter drug as a treatment for a daytime sleepiness condition.

The United States market has experienced a positive trend, rising 1.2% over the last week and climbing 24% in the past year, with earnings anticipated to grow by 15% annually in the coming years. In ...

Conagra is facing significant operational challenges, but the valuation is now compelling enough to reward buyers despite the ...

The state of California banned the Red No. 3 dye and three other food additives in 2023, which gave manufacturers until 2027 ...

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, ...

The results were stunning. So too was the nationality of the company behind them. Akeso, a biotech firm, is Chinese.

From skincare to supplements, these gift options are designed to pamper the mom who has it all and bring a little extra ...

CR tested 58 dog foods from brands including Blue Buffalo, Hill’s Science Diet, and Purina for key nutrients and dangerous ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

Factors like inflation, supply chain disturbances, and evolving consumer preferences have caused food prices to surge ...